JP2008540533A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008540533A5 JP2008540533A5 JP2008511215A JP2008511215A JP2008540533A5 JP 2008540533 A5 JP2008540533 A5 JP 2008540533A5 JP 2008511215 A JP2008511215 A JP 2008511215A JP 2008511215 A JP2008511215 A JP 2008511215A JP 2008540533 A5 JP2008540533 A5 JP 2008540533A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- glycol
- nonionic surfactant
- group
- poloxamine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 30
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 18
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 18
- 229920001987 poloxamine Polymers 0.000 claims 16
- 239000002736 nonionic surfactant Substances 0.000 claims 15
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 9
- 239000003795 chemical substances by application Substances 0.000 claims 6
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims 6
- QEFAQIPZVLVERP-UHFFFAOYSA-N nepafenac Chemical compound NC(=O)CC1=CC=CC(C(=O)C=2C=CC=CC=2)=C1N QEFAQIPZVLVERP-UHFFFAOYSA-N 0.000 claims 5
- 229960001002 nepafenac Drugs 0.000 claims 5
- 239000008181 tonicity modifier Substances 0.000 claims 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 5
- 239000003732 agents acting on the eye Substances 0.000 claims 4
- 229940023490 ophthalmic product Drugs 0.000 claims 4
- 239000003755 preservative agent Substances 0.000 claims 3
- 230000002335 preservative effect Effects 0.000 claims 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims 2
- XPFCZYUVICHKDS-UHFFFAOYSA-N 3-methylbutane-1,3-diol Chemical compound CC(C)(O)CCO XPFCZYUVICHKDS-UHFFFAOYSA-N 0.000 claims 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims 2
- 239000004386 Erythritol Substances 0.000 claims 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000022873 Ocular disease Diseases 0.000 claims 2
- 206010038935 Retinopathy sickle cell Diseases 0.000 claims 2
- OWBTYPJTUOEWEK-UHFFFAOYSA-N butane-2,3-diol Chemical compound CC(O)C(C)O OWBTYPJTUOEWEK-UHFFFAOYSA-N 0.000 claims 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 claims 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims 2
- 229940009714 erythritol Drugs 0.000 claims 2
- 235000019414 erythritol Nutrition 0.000 claims 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- SLCVBVWXLSEKPL-UHFFFAOYSA-N neopentyl glycol Chemical compound OCC(C)(C)CO SLCVBVWXLSEKPL-UHFFFAOYSA-N 0.000 claims 2
- 229940100654 ophthalmic suspension Drugs 0.000 claims 2
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 claims 2
- 230000002207 retinal effect Effects 0.000 claims 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims 2
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 claims 2
- -1 1,3-butylene Chemical group 0.000 claims 1
- 229940058015 1,3-butylene glycol Drugs 0.000 claims 1
- 229940122072 Carbonic anhydrase inhibitor Drugs 0.000 claims 1
- 206010055665 Corneal neovascularisation Diseases 0.000 claims 1
- 206010058202 Cystoid macular oedema Diseases 0.000 claims 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000001344 Macular Edema Diseases 0.000 claims 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims 1
- 201000002154 Pterygium Diseases 0.000 claims 1
- 201000007527 Retinal artery occlusion Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 206010039705 Scleritis Diseases 0.000 claims 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 230000002491 angiogenic effect Effects 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 229940121375 antifungal agent Drugs 0.000 claims 1
- 239000003429 antifungal agent Substances 0.000 claims 1
- 239000007900 aqueous suspension Substances 0.000 claims 1
- 229960000722 brinzolamide Drugs 0.000 claims 1
- HCRKCZRJWPKOAR-JTQLQIEISA-N brinzolamide Chemical compound CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 HCRKCZRJWPKOAR-JTQLQIEISA-N 0.000 claims 1
- 235000019437 butane-1,3-diol Nutrition 0.000 claims 1
- LVGQIQHJMRUCRM-UHFFFAOYSA-L calcium bisulfite Chemical compound [Ca+2].OS([O-])=O.OS([O-])=O LVGQIQHJMRUCRM-UHFFFAOYSA-L 0.000 claims 1
- 235000010260 calcium hydrogen sulphite Nutrition 0.000 claims 1
- GBAOBIBJACZTNA-UHFFFAOYSA-L calcium sulfite Chemical compound [Ca+2].[O-]S([O-])=O GBAOBIBJACZTNA-UHFFFAOYSA-L 0.000 claims 1
- 235000010261 calcium sulphite Nutrition 0.000 claims 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 claims 1
- 239000002738 chelating agent Substances 0.000 claims 1
- 150000003841 chloride salts Chemical class 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 201000000159 corneal neovascularization Diseases 0.000 claims 1
- 201000010206 cystoid macular edema Diseases 0.000 claims 1
- 229960003957 dexamethasone Drugs 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 201000011190 diabetic macular edema Diseases 0.000 claims 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 claims 1
- 206010014801 endophthalmitis Diseases 0.000 claims 1
- 229960001048 fluorometholone Drugs 0.000 claims 1
- FAOZLTXFLGPHNG-KNAQIMQKSA-N fluorometholone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FAOZLTXFLGPHNG-KNAQIMQKSA-N 0.000 claims 1
- 229960000890 hydrocortisone Drugs 0.000 claims 1
- 230000000642 iatrogenic effect Effects 0.000 claims 1
- 201000004614 iritis Diseases 0.000 claims 1
- 206010023332 keratitis Diseases 0.000 claims 1
- 229960001798 loteprednol Drugs 0.000 claims 1
- YPZVAYHNBBHPTO-MXRBDKCISA-N loteprednol Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)OCCl)[C@@H]4[C@@H]3CCC2=C1 YPZVAYHNBBHPTO-MXRBDKCISA-N 0.000 claims 1
- LPHFLPKXBKBHRW-UHFFFAOYSA-L magnesium;hydrogen sulfite Chemical compound [Mg+2].OS([O-])=O.OS([O-])=O LPHFLPKXBKBHRW-UHFFFAOYSA-L 0.000 claims 1
- JESHZQPNPCJVNG-UHFFFAOYSA-L magnesium;sulfite Chemical compound [Mg+2].[O-]S([O-])=O JESHZQPNPCJVNG-UHFFFAOYSA-L 0.000 claims 1
- 229910001510 metal chloride Inorganic materials 0.000 claims 1
- 235000010298 natamycin Nutrition 0.000 claims 1
- 239000004311 natamycin Substances 0.000 claims 1
- NCXMLFZGDNKEPB-FFPOYIOWSA-N natamycin Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C[C@@H](C)OC(=O)/C=C/[C@H]2O[C@@H]2C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 NCXMLFZGDNKEPB-FFPOYIOWSA-N 0.000 claims 1
- 229960003255 natamycin Drugs 0.000 claims 1
- 239000003002 pH adjusting agent Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims 1
- DJEHXEMURTVAOE-UHFFFAOYSA-M potassium bisulfite Chemical compound [K+].OS([O-])=O DJEHXEMURTVAOE-UHFFFAOYSA-M 0.000 claims 1
- 229940099427 potassium bisulfite Drugs 0.000 claims 1
- 235000010259 potassium hydrogen sulphite Nutrition 0.000 claims 1
- BHZRJJOHZFYXTO-UHFFFAOYSA-L potassium sulfite Chemical compound [K+].[K+].[O-]S([O-])=O BHZRJJOHZFYXTO-UHFFFAOYSA-L 0.000 claims 1
- 235000019252 potassium sulphite Nutrition 0.000 claims 1
- 229960005205 prednisolone Drugs 0.000 claims 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims 1
- 229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 claims 1
- 210000001957 retinal vein Anatomy 0.000 claims 1
- 208000004644 retinal vein occlusion Diseases 0.000 claims 1
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 claims 1
- 229960002586 roflumilast Drugs 0.000 claims 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims 1
- 229940001584 sodium metabisulfite Drugs 0.000 claims 1
- 235000010262 sodium metabisulphite Nutrition 0.000 claims 1
- 235000010265 sodium sulphite Nutrition 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 239000000375 suspending agent Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67951005P | 2005-05-10 | 2005-05-10 | |
| US60/679,510 | 2005-05-10 | ||
| PCT/US2006/017607 WO2006121964A2 (en) | 2005-05-10 | 2006-05-08 | Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a glycol tonicity-adjusting agent, use of said composition for the manufacture of a medicament for treating ophthalmic disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008540533A JP2008540533A (ja) | 2008-11-20 |
| JP2008540533A5 true JP2008540533A5 (cg-RX-API-DMAC7.html) | 2009-04-16 |
| JP4968955B2 JP4968955B2 (ja) | 2012-07-04 |
Family
ID=37087751
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008511215A Expired - Fee Related JP4968955B2 (ja) | 2005-05-10 | 2006-05-08 | 眼用薬物、ポロキサミンおよびグリコール張度調整剤を含有する眼用懸濁液、ならびに眼の障害を処置するための医薬の製造のためのこの組成物の使用 |
Country Status (19)
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1885336T3 (pl) * | 2005-05-10 | 2009-08-31 | Alcon Inc | Kompozycja w postaci zawiesiny zawierająca substancję aktywną, poloksamerowy lub meroksapolowy surfaktant i glikol oraz zastosowanie kompozycji do wytwarzania leku do leczenia chorób oczu |
| TW200812575A (en) * | 2006-04-28 | 2008-03-16 | Alcon Inc | Formulations containing amide derivatives of carboxylic acid NSAIDs for topical administration to the eye |
| TW201023912A (en) | 2008-12-05 | 2010-07-01 | Alcon Res Ltd | Pharmaceutical suspension |
| WO2010101989A1 (en) | 2009-03-03 | 2010-09-10 | Alcon Research, Ltd. | PHARMACEUTICAL COMPOSITION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE |
| KR20110123789A (ko) * | 2009-03-03 | 2011-11-15 | 알콘 리서치, 리미티드 | 리셉터 티로신 키나제 저해(ＲＴＫｉ) 화합물을 눈에 전달하기 위한 약학 조성물 |
| PL2586426T3 (pl) * | 2009-12-03 | 2016-01-29 | Alcon Res Ltd | Zawiesiny zawierające nanocząsteczkowe polimery karboksywinylowe |
| CA2783699C (en) | 2009-12-08 | 2019-01-15 | Case Western Reserve University | Primary amine compounds for treating ocular disorders |
| EP2609933A4 (en) * | 2010-08-27 | 2014-04-09 | Wakamoto Pharma Co Ltd | AQUEOUS COMPOSITION FOR ADMINISTRATION |
| US9408797B2 (en) | 2011-06-03 | 2016-08-09 | Allergan, Inc. | Dermal filler compositions for fine line treatment |
| CN104706579A (zh) * | 2015-03-12 | 2015-06-17 | 广州仁恒医药科技有限公司 | 一种夫西地酸滴眼液及其制备方法 |
| CN111285845B (zh) * | 2020-02-11 | 2021-01-01 | 深圳厚存纳米药业有限公司 | 末端官能团化的泊洛沙胺衍生物 |
| US12049606B2 (en) * | 2021-01-12 | 2024-07-30 | Johnson & Johnson Vision Care, Inc. | Compositions for ophthalmologic devices |
| JP2024506384A (ja) * | 2021-02-10 | 2024-02-13 | イオリクス セラピューティクス，インコーポレーテッド | ロフルミラストの眼科的送達方法 |
| CN116867480A (zh) * | 2021-02-10 | 2023-10-10 | 洛利克斯治疗有限公司 | 眼部递送罗氟司特的方法 |
| CA3231766A1 (en) | 2021-09-22 | 2023-03-30 | Elizabeth W. JEFFORDS | Methods of treating ocular inflammatory diseases |
| WO2024058848A1 (en) * | 2022-09-15 | 2024-03-21 | Arcutis Biotherapeutics, Inc. | Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4313949A (en) * | 1979-09-26 | 1982-02-02 | A. H. Robins Company, Inc. | Method of producing an inhibitory effect on blood platelet aggregation |
| AU610979B2 (en) * | 1987-12-25 | 1991-05-30 | Santen Pharmaceutical Co. Ltd. | Antiallergic eye drop |
| CA1325382C (en) * | 1988-01-27 | 1993-12-21 | Takahiro Ogawa | Locally administrable therapeutic composition for inflammatory disease |
| US5521222A (en) * | 1989-09-28 | 1996-05-28 | Alcon Laboratories, Inc. | Topical ophthalmic pharmaceutical vehicles |
| US5461081A (en) * | 1989-09-28 | 1995-10-24 | Alcon Laboratories, Inc. | Topical ophthalmic pharmaceutical vehicles |
| US5369095A (en) * | 1990-02-14 | 1994-11-29 | Alcon Laboratories, Inc. | Compositions and method comprising substituted glycosides as mucus membrane permeation enhancers |
| US5631005A (en) * | 1994-09-21 | 1997-05-20 | Alcon Laboratories, Inc. | Use of amidoamines in ophthalmic compositions |
| US5631004A (en) * | 1993-09-30 | 1997-05-20 | Alcon Laboratories, Inc. | Use of sustained release antibiotic compositions in ophthalmic surgical procedures |
| US5540930A (en) * | 1993-10-25 | 1996-07-30 | Pharmos Corporation | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
| US5475034A (en) * | 1994-06-06 | 1995-12-12 | Alcon Laboratories, Inc. | Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders |
| JPH10158188A (ja) * | 1996-11-29 | 1998-06-16 | Senju Pharmaceut Co Ltd | 角膜治療用組成物 |
| PT970175E (pt) * | 1997-07-29 | 2003-02-28 | Alcon Lab Inc | Solucoes de acondicionamento para cuidar de lentes de contacto rigidas |
| US6037328A (en) * | 1998-12-22 | 2000-03-14 | Bausch & Lomb Incorporated | Method and composition for rewetting and preventing deposits on contact lens |
| US6482799B1 (en) * | 1999-05-25 | 2002-11-19 | The Regents Of The University Of California | Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial |
| IT1313610B1 (it) * | 1999-08-09 | 2002-09-09 | S I F I Societa Ind Farmaceuti | Processo per la preparazione di formulazioni acquose per uso oftalmico |
| US6582724B2 (en) * | 1999-12-16 | 2003-06-24 | Dermatrends, Inc. | Dual enhancer composition for topical and transdermal drug delivery |
| EP1249249A1 (en) * | 2000-12-12 | 2002-10-16 | Menicon Co., Ltd. | Ophthalmic composition |
| AR030346A1 (es) * | 2000-08-14 | 2003-08-20 | Alcon Inc | Metodo de tratamiento de desordenes neurodegenerativos de la retina y cabeza de nervio optico |
| PE20020578A1 (es) * | 2000-10-10 | 2002-08-14 | Upjohn Co | Una composicion de antibiotico topico para el tratamiento de infecciones oculares |
| US20020115578A1 (en) * | 2000-12-14 | 2002-08-22 | Groemminger Suzanne F. | Composition for cleaning and wetting contact lenses |
| AU2002247284A1 (en) * | 2001-04-02 | 2002-10-15 | Alcon, Inc. | Method of treating ocular inflammatory and angiogenesis-related disorders using an amide derivative of flubiprofen or ketorolac |
| JP2003137775A (ja) * | 2001-10-31 | 2003-05-14 | Menicon Co Ltd | 眼科用組成物 |
| US20030133905A1 (en) * | 2001-12-20 | 2003-07-17 | Zhenze Hu | Composition for treating contact lenses in the eye |
| US6765001B2 (en) * | 2001-12-21 | 2004-07-20 | Medicis Pharmaceutical Corporation | Compositions and methods for enhancing corticosteroid delivery |
| US7119112B2 (en) * | 2002-02-28 | 2006-10-10 | Icagen, Inc. | Sulfonamides as potassium channel blockers |
| US20040029771A1 (en) * | 2002-02-28 | 2004-02-12 | Icagen, Inc. | Methods for treating diseases related to intraocular pressure |
| US20040115270A1 (en) * | 2002-12-13 | 2004-06-17 | Dharmendra Jani | Absorption and controlled release of polyethers from hydrogel biomaterials |
| EP1611883A1 (en) * | 2003-03-26 | 2006-01-04 | Menicon Co., Ltd. | Composition for ophthalmic use |
| TWI358290B (en) * | 2004-12-02 | 2012-02-21 | Alcon Inc | Topical nepafenac formulations |
| PL1885336T3 (pl) * | 2005-05-10 | 2009-08-31 | Alcon Inc | Kompozycja w postaci zawiesiny zawierająca substancję aktywną, poloksamerowy lub meroksapolowy surfaktant i glikol oraz zastosowanie kompozycji do wytwarzania leku do leczenia chorób oczu |
-
2006
- 2006-05-08 SI SI200630144T patent/SI1906916T1/sl unknown
- 2006-05-08 WO PCT/US2006/017607 patent/WO2006121964A2/en not_active Ceased
- 2006-05-08 EP EP06759259A patent/EP1906916B1/en not_active Not-in-force
- 2006-05-08 ZA ZA200709296A patent/ZA200709296B/xx unknown
- 2006-05-08 AT AT06759259T patent/ATE412402T1/de active
- 2006-05-08 CN CN200680016190XA patent/CN101175476B/zh not_active Expired - Fee Related
- 2006-05-08 DK DK06759259T patent/DK1906916T3/da active
- 2006-05-08 PT PT06759259T patent/PT1906916E/pt unknown
- 2006-05-08 PL PL06759259T patent/PL1906916T3/pl unknown
- 2006-05-08 KR KR1020077027978A patent/KR20080011311A/ko not_active Ceased
- 2006-05-08 BR BRPI0608774-4A patent/BRPI0608774A2/pt not_active IP Right Cessation
- 2006-05-08 ES ES06759259T patent/ES2313670T3/es active Active
- 2006-05-08 CA CA002607014A patent/CA2607014A1/en not_active Abandoned
- 2006-05-08 US US11/429,736 patent/US20060257486A1/en not_active Abandoned
- 2006-05-08 AU AU2006244245A patent/AU2006244245B2/en not_active Ceased
- 2006-05-08 JP JP2008511215A patent/JP4968955B2/ja not_active Expired - Fee Related
- 2006-05-08 MX MX2007014084A patent/MX2007014084A/es active IP Right Grant
- 2006-05-08 DE DE602006003438T patent/DE602006003438D1/de active Active
-
2008
- 2008-12-10 CY CY20081101427T patent/CY1108676T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008540532A5 (cg-RX-API-DMAC7.html) | ||
| JP4968954B2 (ja) | 活性成分、ポロキサマー界面活性剤もしくはメロキサポール界面活性剤およびグリコールを含有する懸濁処方物、ならびに眼の障害を処置するための医薬の製造のためのその使用 | |
| JP2008540533A5 (cg-RX-API-DMAC7.html) | ||
| JP4968955B2 (ja) | 眼用薬物、ポロキサミンおよびグリコール張度調整剤を含有する眼用懸濁液、ならびに眼の障害を処置するための医薬の製造のためのこの組成物の使用 | |
| RU2009149687A (ru) | Фармацевтические композиции и способы лечения сухих кератитов | |
| JP4968844B2 (ja) | 局所用ネパフェナク処方物 | |
| JP2015110672A (ja) | ビマトプロストおよびブリモニジンの固定用量の組み合わせ | |
| JP2021046394A5 (cg-RX-API-DMAC7.html) | ||
| US20050031652A1 (en) | Compositions and methods comprising memantine and polyanionic polymers | |
| JP2004520267A (ja) | ベンゾイルフェニル酢酸を使用して、血管形成関連障害を処置するための方法 | |
| JP5072294B2 (ja) | アシタザノラスト含有組成物 | |
| JP5514270B2 (ja) | アシタザノラスト含有組成物 | |
| US20200197398A1 (en) | Netarsudil and low-dose brimonidine combination and uses thereof | |
| WO2018144742A1 (en) | Compounds and compositions for the treatment of ophthalmic disorders | |
| US20050147584A1 (en) | Compositions and methods comprising memantine and polyanionic polymers |